Colorectal cancer is the third most common type of cancer in the world, with approximately 1.8 million new cases diagnosed globally in 2022. The risk of developing CRC during a man's lifetime is about 1 in 23, while for women it is 1 in 25. BRAF mutations are estimated to occur in 8%-10% of metastatic colorectal cancer patients, who have a poor prognosis. BRAF V600E mutation is the most common type of BRAF mutation, with CRC patients carrying BRAF V600E mutation having more than twice the risk of death compared to those without the mutation. Despite the high unmet medical needs for patients with BRAF V600E mutation metastatic colorectal cancer, there have been no approved biomarker-driven treatments targeting these treatment-naïve patients before.